Simon-Kucher Appoints Five New Partners in its Global Healthcare & Life Sciences Sector
Boston/Toronto, June 26, 2024 – Simon-Kucher, a global consulting firm, has appointed Bryan Ciampa, Christoph Engelke, Sinead O’Sullivan-Carty, Stéphane Ricoult, and Dmitry Goldenberg as the newest Partners in its global Healthcare & Life Sciences sector. The five new Partners are spread across North America (Ciampa is based out of the firm’s Toronto office, Goldenberg is based out of New York, and Ricoult is based out of Boston) and Europe (Engelke works from the Munich office and O’Sullivan-Carty is based in London).
Ciampa has been with the firm since 2014 and advises pharmaceutical and biotech clients with global pricing & market access (P&MA) and commercial challenges. His specialties include optimal (launch and lifecycle management) P&MA strategies, early product development, wider portfolio strategy, alternative access solutions / innovative contracting, price negotiation excellence, payer trends and engagement, payer value story development, and international reference pricing considerations. He has experience in a broad range of therapeutic areas, including oncology and rare diseases, and has worked in all major healthcare markets across the Americas, Europe, and Asia-Pacific. Ciampa earned a BCom at McGill University’s Desautels Faculty of Management in Montreal, Canada, where he majored in Finance.
Engelke specializes in developing and optimizing pricing and market access strategies for pharmaceutical companies throughout every phase of the product lifecycle. His expertise is centered in the German market, where he strategically prepares and executes price negotiations with payers within the German AMNOG framework. Since joining Simon-Kucher, Engelke has successfully supported large pharmaceutical and biotech companies, guiding them through challenges within the German P&R process and navigating groundbreaking pharmaceutical innovations, from oncology drugs to highly specialized gene therapies. Engelke holds an MSc in Mechanical Engineering with a specialization in Aerospace Engineering from the Technical University of Munich.
O’Sullivan-Carty joined the firm in 2011 and has been pivotal in managing and consulting significant global projects for industry leaders. Through her work at Simon-Kucher, O’Sullivan-Carty has extensive experience in the Life Sciences industry, leading numerous projects for top-tier companies and advising them on their key business initiatives and obstacles. Her expertise lies in global launch pricing, product strategy, value communication, and revenue optimization. O'Sullivan-Carty holds a Bachelor of Arts in Biology from Oxford University.
Ricoult advises both leading pharma and biotech companies in a variety of therapeutic areas including oncology, immunology, metabolic diseases, rare diseases, and vaccines. Since joining the firm, he has focused on numerous strategic topics, including new product planning, competitive strategies, and pricing and market access across a product’s lifecycle. Through his work at Simon-Kucher supporting more than 25 pharma and biotech companies, he has developed an in-depth knowledge of the US healthcare system as well as other European and key global markets. Ricoult completed his PhD in Biological and Biomedical Sciences from Harvard University and earned his BS in Biology from Massachusetts Institute of Technology. He is an author on multiple peer-reviewed scientific publications and has extensive experience in biomedical research.
Goldenberg has nearly two decades of experience across the consulting and pharmaceutical industry helping companies develop pricing, market access, and commercial strategy. Most recently, he was with Pfizer as a member of the Oncology Global Access Strategy & Pricing team, where he developed market access strategy for the breast cancer franchise and led multiple organizational readiness initiatives. During his time at Pfizer, he developed global pricing strategy for numerous brands, created access and commercial brand deliverables, and partnered with more than 40 countries around the world to support payer negotiations.
“In our ongoing dedication to the pharmaceutical and biotech industry, we proudly announce the appointment of our new Partners to our global Healthcare & Life Science sector at Simon-Kucher. With strategic placements in North America and Europe, our team further expands its footprint and capabilities, poised to deliver innovative solutions and transformative insights to our clients worldwide. This expansion marks a pivotal moment in our commitment to driving progress and innovation in the healthcare industry.” Joerg Kruetten, Global Head of Healthcare & Life Sciences at Simon-Kucher.
“We are thrilled with the appointment of the five Partners to our Healthcare & Life Sciences sector. Their expertise and passion for consulting and the healthcare industry are an ideal fit for our organization and reinforce our commitment to better market access in pharma and better growth all around.” Dr. Allison Dupuy, Partner, Co-Managing Director US and Canada, Member of the Board, and Head of Healthcare & Life Sciences in the Americas.
Simon-Kucher’s globally recognized Healthcare & Life Sciences sector has led the way in the industry for nearly 40 years, helping pharmaceutical, medical technology, and consumer healthcare companies identify, enhance, and realize the true value of their innovations.
For further information, please contact:
Niki Irby
niki.irby@simon-kucher.com
About Simon-Kucher
Simon-Kucher is a global consultancy with more than 2,000 employees in 30 countries. Our sole focus is on unlocking better growth that drives measurable revenue and profit for our clients. We achieve this by optimizing every lever of their commercial strategy – product, price, innovation, marketing, and sales – based on deep insights into what customers want and value. With nearly 40 years of experience in monetization topics of all kinds, we are regarded as the world’s leading pricing and growth specialist.